Inhibitor Therapeutics, Inc.
INTI· OTC
INTIInhibitor Therapeutics, Inc.
Filed Aug 14, 2026 · 10-Q · 45 days after period end · 0001493152-26-038288
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$613.93K | -$659.94K | -$501.69K | -$654.52K |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end
